IV Potassium Administration in Renal Replacement Therapy and Hypophosphatemia

Renal Replacement Therapy Considerations

Avoid intravenous potassium administration in patients receiving continuous kidney replacement therapy (CKRT); instead, use potassium‑containing dialysis solutions (approximately 4 mEq/L) to maintain serum potassium safely – Clinical Nutrition guideline (2021) 1

Reserve intravenous potassium phosphate for patients with documented hypophosphatemia (serum phosphate < 0.32 mmol/L or < 1.0 mg/dL); the indication should be confirmed before use – Clinical Nutrition guideline (2018) 2
Recognize that hypophosphatemia can lead to muscle weakness, respiratory failure, and cardiac dysfunction; these potential complications must be balanced against the slower correction rate and higher potassium load associated with potassium phosphate – Clinical Nutrition guideline (2018) 3

The American College of Physicians recommends avoiding potassium phosphate administration in patients with significant renal impairment (CrCl <20 mL/min) without careful monitoring 4

The European Society of Intensive Care Medicine suggests monitoring serum potassium levels regularly when administering potassium phosphate, as the high potassium load can cause hyperkalemia, particularly in patients with impaired renal function or those on medications affecting potassium homeostasis 5, 4